A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2022-06-24
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-07-17 (study day 16); relationship: not assessed
moderate
assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-09-16 (study day 77); relationship: N
mild
assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-09-16 (study day 77); relationship: not assessed
Data queries
No data queries.